Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

[Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].

Intrahepatic HBV DNA As a Predictor of Antivirus Treatment Efficacy in HBeAg-positive Chronic Hepatitis B Patients.

The Impact of Early Rapid Virological Response on the Outcomes of Hepatitis B Associated Acute on Chronic Liver Failure During Antiviral Treatment

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Role of Intrahepatic HBV DNA in Antivirus Therapy

[Effects of Antiviral Agents on Intrahepatic Ccc DNA in HBeAg-positive Chronic Hepatitis B Patients].

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

Relationship Between the Antiviral Effect and Changes in Helper T (th) Cytokine Levels in the Treatment of Chronic Hepatitis B Using Lamivudine Combined with Alpha Interferon

Effects of Antiviral Effects of Agents and Prognosis of Chronic Hepatitis B

Effects of Antiviral Agents and HBV Genotypes on Intrahepatic Covalently Closed Circular DNA in HBeAg-positive Chronic Hepatitis B Patients

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Responding to Peg-IFN Treatment

Study on the Efficacy and Related Factors of Antiviral Therapy in Chronic Hepatitis B

A Study on the Clinical and Pathological Efficacy of Lamivudine in the Treatment of Chronic Hepatitis B

[525] EVALUATION OF EFFICIENCY OF SEQUENTIAL THERAPY WITH INTERFERON AND LAMIVUDINE FROM CHANGES OF HBV Cccdna IN LIVER IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS

[The Analyse of Effectiveness in HBeAg-positive Chronic Viral Hepatitis B Treated by Adefovir Dipivoxil Combined with Bicyclol].

Effect of Telbivudine Therapy on the Cellular Immune Response in Chronic Hepatitis B

[The Relationship Between HBV Genotypes and the Efficacy of Antiviral Therapies in Hepatitis B E Antigen- Positive Patients].

Clinical Trail of Decoction of Tonifying Qi Activating Blood and Detoxifcation in the Treatment of Chronic Hepatitis B Patients with Alanine Aminotransferase Less than Two-time upper Limits of Normal Level

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD